Status:
UNKNOWN
Anti-inflammatories and Adolescent Schizophrenia
Lead Sponsor:
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Conditions:
Schizophrenia
Eligibility:
All Genders
12-17 years
Phase:
PHASE4
Brief Summary
A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and cognition of adolescents with schizophrenia
Detailed Description
Patients will be evaluated to confirm the diagnosis of schizophrenia, duration of the disease and record a history of atopic diseases or recurrent infections throughout life. The PANSS, PSP, and MCCB ...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or schizophreniform disorder.
- Patients in their first psychotic episode or previously diagnosed
- No specific pharmacological treatment (antipsychotic at therapeutic doses in regular doses) in the previous two weeks.
- Have a responsible parent or guardian.
Exclusion
- Active infection
- Chronic somatic diseases, including autoimmune diseases
- Comorbidity with anorexia, substance use disorders
- Pregnancy
- Use of anti-inflammatory medications or antibiotics
Key Trial Info
Start Date :
February 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04020588
Start Date
February 25 2019
End Date
December 1 2020
Last Update
September 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Psiquiatrico Infantil
Mexico City, Ni Ee.uu. Ni Canadá, Mexico, 14080